Iterum Therapeutics plc (NASDAQ:ITRM), a pharmaceutical company with a market capitalization of $53.43 million, has reported a regulatory compliance issue with the Nasdaq Stock Market. According to ...

SAN DIEGO and CALGARY, AB - Oncolytics Biotech Inc. (NASDAQ: NASDAQ:ONCY) (TSX: ONC), a biotechnology firm focused on immunotherapy for cancer, has received a notification from the Nasdaq regarding ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Wide-moat GE HealthCare, or GEHC, is a top three global leader in the medical imaging market. It has a firmly established footprint in hospitals and health networks around the world, and it is ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

West Pharma’s financial strength is solid, and the firm has historically managed a very strong balance sheet. As of year-end 2023, West had total debt outstanding of $206 million. West has ...

Moderna’s consensus price target has significantly declined from $119.26 to $47.5, indicating a cautious outlook from ...

Following the earnings announcement, WST stock plummeted 38% due to its disappointing guidance. Over a broader timeframe, its ...

In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal anticipated cuts to the company’s digital team.

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the decline of its Covid business.

Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...

West Pharmaceutical reported Q4 earnings and revenue above expectations but issued a weak 2025 forecast. William Blair ...